Trial · NCT00082875
Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma
NCT00082875, Phase 2, Terminated, National Cancer Institute (NCI)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma. Trials, record NCT00082875. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00082875
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma
- NCT number
- NCT00082875
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 56 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Stage III Melanoma, Stage IV Melanoma
- Interventions
- cilengitide, pharmacological study, laboratory biomarker analysis
- First posted
- 2004-05-19
- Last updated
- 2013-06-05
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PFS | At 8 weeks | Each dose of EMD 121974 will be analyzed separately. |
| Secondary | Response rate, calculated by the ratio of the number of (CR + PR) / total number of treated patients | Up to 4 years | |
| Secondary | PFS | Up to 4 years | For each dose of EMD 121974, Kaplan-Meier life table methods and Cox proportional hazards regression modeling will be utilized to analyze progression-free survival. |
| Secondary | Overall survival | Up to 4 years | For each dose of EMD 121974, Kaplan-Meier life table methods and Cox proportional hazards regression modeling will be utilized to analyze overall survival. |
| Secondary | Incidence of adverse events graded according to CTCAE version 3.0 | Up to 4 years | Adverse events will be tabulated by dose of EMD 121974 and toxicity grade. |
| Secondary | Population Pharmacokinetics of EMD 121974, including Cmax, tmax, AUClast, t1/2, AUCinf, CL, Vz | Before and 2, 4, and 24 hours after dose of the first dose of courses 1 and 2 and before and 4 hours after dose of the third dose of courses 1 and 2 | Mean and SD will be estimated for each parameter except for tmax, where the median and range will be reported. Plasma concentrations and pharmacokinetic parameters for each dose will be summarized using descriptive statistics and the mean plasma concentrations for each dose will be plotted versus time. Pharmacokinetic parameters will be compared among doses using graphical and statistical analyses. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00082875
GET https://conductscience.org/api/trials/v1/NCT00082875/registered